A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with NPM1 and IDH2 mutations

Syed Muhammad Waqar Haider; Mehwish Zehra; Nikesh N Shah; Eduardo M Sotomayor; David M Swoboda

doi:10.1016/j.lrr.2024.100461

A comprehensive case study on successful multimodal therapy in philadelphia chromosome-positive acute myeloid leukemia with NPM1 and IDH2 mutations

Leuk Res Rep. 2024 Apr 30:21:100461. doi: 10.1016/j.lrr.2024.100461. eCollection 2024.

Authors

Syed Muhammad Waqar Haider¹, Mehwish Zehra², Nikesh N Shah³, Eduardo M Sotomayor³, David M Swoboda³

Affiliations

¹ Imran Pediatric Clinic and Vaccination Centre, Karachi, Sindh, Pakistan.
² Indus Hospital And Health Network, Karachi, Sindh, Pakistan.
³ Tampa General Hospital Cancer Institute, Tampa, FL, USA.

Abstract

A 67-year-old female came to Tampa General Hospital with Philadelphia chromosome-positive (Ph+) acute myeloid leukemia (AML) featuring an intriguing combination of mutations, including NPM1 and IDH2 mutations. Novel combination therapy with azacitidine, venetoclax and ponatinib allowed her to successfully achieve a complete response (CR) and undergo an allogeneic hematopoietic stem cell transplant (HSCT). This case report provides an overview of her clinical course, emphasizing the significance of integrated therapy and the challenges associated with balancing treatment for AML. It also underscores the importance of a multidisciplinary approach and careful monitoring of patients with complex hematologic conditions.

Keywords: Acute myeloid leukemia; IDH2 mutation; NPM1 mutation; Philidelphia chromosome positive; Tyrosine kinase inhibitors.

Publication types

Case Reports